Please login to read the full article.
Scrip Regulatory Affairs
Value-based pricing in the UK and the possible role of NICE
13 December 2010
Elizabeth Sukkar
Please login to read the full article.
Not a subscriber ? Request a FREE Trial
Subscribe to Regulatory Affairs Pharma
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
- NICE value-based pricing role to be vital, says England's department of health
- UK PIP report highlights need to improve adverse incident reporting; registries urged
- UK PIP report largely vindicates EU medtech system but highlights need for improvements
- Will accelerated approval, antibiotic add-ons bog down PDUFA in US?
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
Other Informa Analysis
EDITORIALS
Regulatory Affairs Pharma Editorials
Other Informa Editorials
FEATURES
Regulatory Affairs Pharma Features
Other Informa Features
COMMENT
Regulatory Affairs Pharma Comment
Other Informa Comments
